Q&A: Addressing the Hidden Burden of MASLD in Clinical Practice
Metabolic dysfunction-associated steatotic liver disease (MASLD) remains largely underdiagnosed and asymptomatic, creating major opportunities for pharmacists to drive early identification, lifestyle intervention, and metabolic risk management.
In an interview with Pharmacy Times, Jiyeon Oh, MD, first author and staff at the Department of Medicine at Kyung Hee University College of Medicine in Seoul, South Korea; Min Seo Kim, MD, MS, corresponding author and staff at the Cardiovascular Disease Initiative, Broad Institute; and Dong Keon Yon, MD, PhD, corresponding author and assistant professor in the department of pediatrics at Kyung Hee University, discussed the clinical implications of metabolic dysfunction-associated steatotic liver disease (MASLD), including gaps in detection, treatment limitations, and opportunities for pharmacist involvement.1